Focused On-demand Library for General transcription factor IIF subunit 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P13984

UPID:

T2FB_HUMAN

Alternative names:

General transcription factor IIF 30 kDa subunit; Transcription initiation factor IIF subunit beta; Transcription initiation factor RAP30

Alternative UPACC:

P13984; A6NNS5; Q5W0H3

Background:

General transcription factor IIF subunit 2, also known as TFIIF, plays a pivotal role in the initiation of gene transcription by RNA polymerase II. It functions alongside TFIIB to recruit RNA polymerase II to the initiation complex, facilitating the transcription process. This protein is also recognized by its alternative names, including General transcription factor IIF 30 kDa subunit, Transcription initiation factor IIF subunit beta, and Transcription initiation factor RAP30.

Therapeutic significance:

Understanding the role of General transcription factor IIF subunit 2 could open doors to potential therapeutic strategies. Its critical function in gene transcription initiation positions it as a key player in cellular processes, suggesting that modulation of its activity could influence gene expression patterns involved in various diseases.